ImmuPharma plc (LON:IMM – Get Free Report) shares fell 5.6% during trading on Friday . The company traded as low as GBX 1.03 ($0.01) and last traded at GBX 1.15 ($0.01). 845,057 shares traded hands during trading, a decline of 7% from the average session volume of 911,549 shares. The stock had previously closed at GBX 1.22 ($0.02).
ImmuPharma Stock Performance
The stock has a market cap of £5.00 million, a PE ratio of -120.00 and a beta of 1.53. The business has a 50-day moving average of GBX 1.38 and a 200 day moving average of GBX 1.66.
About ImmuPharma
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Featured Stories
- Five stocks we like better than ImmuPharma
- Industrial Products Stocks Investing
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
- Using the MarketBeat Dividend Tax Calculator
- Nebius Group: The Rising Star in AI Infrastructure
- How to Calculate Stock Profit
- MarketBeat Week in Review – 12/30 – 1/03
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
